CK
IONS icon

Carnick & Kubik’s Ionis Pharmaceuticals IONS Stock Holding History

Carnick & Kubik’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-200
Closed -$8.08K – 215
2015
Q3 		$8.08K Buy
+200
New +$10.4K 0.01% 319

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Carnick & Kubik's IONS Position: Q4 2015 in Review

Carnick & Kubik sold out of Ionis Pharmaceuticals (IONS) in Q4 2015, closing a stake of 200 shares — an estimated $8.08K sold.

Carnick & Kubik first reported a position in IONS in Q3 2015 and held it in 1 quarter. The position peaked at $8.08K in Q3 2015. 334 funds tracked by Wall St. Rank hold IONS as of Q4 2015.

  • Carnick & Kubik reported no remaining Ionis Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Carnick & Kubik sold 200 Ionis Pharmaceuticals shares in Q4 2015, an estimated $8.08K.
  • Carnick & Kubik first reported a position in Ionis Pharmaceuticals in Q3 2015 and held it in 1 quarter.
  • Carnick & Kubik's Ionis Pharmaceuticals position peaked at $8.08K in Q3 2015.
  • 334 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2015.

Based on Carnick & Kubik's 13F filing for Q4 2015, filed 11 Feb 2016.